

## **IMPORTANT TAX NOTICE RE: 2022 PFIC Status**

Orion Biotech Opportunities Corp. may be deemed to be classified as a passive foreign investment company (PFIC), as defined in Section 1297(a) of the Internal Revenue Code, for the tax year ended December 31, 2022. Orion Biotech Opportunities Corp. is hereby making available its PFIC Annual Information Statement for the tax year ended December 31, 2022, pursuant to Treasury Regulations Section 1.1295-1(g)(1).

This information is provided to assist Orion Biotech Opportunities Corp. shareholders in making calculations and does not constitute tax advice. The U.S. tax laws regarding PFICs are extremely complex, and shareholders are advised to consult their own tax advisor concerning the overall tax consequences of their respective investment in an indirect ownership of a respective class of shares of Orion Biotech Opportunities Corp. under U.S. federal, state, local and foreign law.

Further information on the PFIC rules is available on the internet at the Internal Revenue Service website.

[remainder of page intentionally left blank]



## **PFIC Annual Information Statement**

This Information Statement relates to the tax year beginning January 1, 2022 and ending December 31, 2022.

The amounts of ordinary income and net capital gains are reflected below. In addition, the amount of cash and the fair market value of other property distributed or deemed distributed by Orion Biotech Opportunities Corp. during the taxable year are as follows:

| Particulars                                  | Amount (USD) |
|--|--------------|
| Cash Distributions                           | 0            |
| Fair Market Value of Property<br>Distributed | 0            |
| Ordinary Income                              | \$1,985,213  |
| Net Capital Gains                            | 0            |

Orion Biotech Opportunities Corp. will permit its shareholders to inspect and copy the permanent books of account, records and such other documents as may be maintained by Orion Biotech Opportunities Corp. that are necessary to establish the Orion Biotech Opportunities Corp. ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. income tax principles.

Please consult your tax advisor to determine your applicable share of Orion Biotech Opportunities Corp.'s ordinary income indicated above based on your ownership in Orion Biotech Opportunities Corp.

Orion Biotech Opportunities Corp. Date: <u>03/22/23</u>

Title: CFO

BDT & MSD PARTNERS 1 Vanderbilt Avenue, 26th Floor New York, NY 10017 bdtmsd.com